Viability of red cells prepared with S-303 pathogen inactivation treatment.

Background: A nucleic acid-targeted pathogen inactivation process with S-303 was developed to treat red blood cells (RBCs).

Study Design And Methods: Three studies in healthy subjects investigated posttransfusion recovery, life span, and immunogenic potential of autologous RBCs treated with S-303 and stored for 35 days. A two-arm trial in 42 subjects (1A) examined recovery of 35-day-old S-303 RBCs after a single transfusion.

Hints to blood groupers, 1950.

Sixty years ago, the premier blood grouping laboratory was that of Robert Race in London. Agglutination tests and blood grouping had provided breakthroughs in immunology, genetics, and the solution of clinical problems. The significance of immunohematology was recognized by the clinical hematology community as a potent force in the expanding field of disorders of the blood and blood-forming organs.

The how and why of exocytic vesicles.

The purpose of this review is to draw the attention of general readers to the importance of cellular exocytic vesiculation as a normal mechanism of development and subsequent adjustment to changing conditions, focusing on red cell (RBC) vesiculation. Recent studies have emphasized the possible role of these microparticles as diagnostic and investigative tools. RBCs lose membrane, both in vivo and during ex vivo storage, by the blebbing of microvesicles from the tips of echinocytic spicules.

Buffering and dilution in red blood cell storage.

Background: Red blood cell (RBC) storage solutions work in a narrow pH range between 7.2 and 6.4.